文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

非洲非B亚型HIV-1中新整合酶突变与基因型DTG耐药相关:DTG RESIST研究

Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究纳入非洲DTG RESIST研究点的382条整合酶序列,用Stanford HIVdb v9.8解读,并以INT-WAS方法识别未归类为主要或辅助INSTI耐药突变的整合酶突变。结果显示,104条(27.2%)序列至少 intermediate 水平DTG耐药,12个未归类突变与预测DTG耐药显著相关,其中V79I和I72L关联最强,部分突变在DTG治疗病毒血症者中富集。

要点

  • 非洲非B亚型中104/382条(27.2%)序列至少 intermediate 水平DTG耐药。
  • 12个未归类INSTI耐药突变的整合酶突变与预测DTG耐药显著相关。
  • V79I(aOR 167.1)和I72L(aOR 65.6)与预测DTG耐药关联最强。

核心结论

  • 在非洲非B亚型HIV-1中,多个未归类为主要或辅助INSTI耐药突变的整合酶氨基酸替换与预测DTG耐药显著相关。
  • DTG耐药进化复杂,可能涉及当前未归类为耐药突变的突变。

研究设计与样本

  • 纳入非洲DTG RESIST研究点的整合酶序列,共382条。
  • 使用Stanford HIVdb v9.8解读序列,并采用限制于整合酶区域的病毒全基因组关联研究样方法(INT-WAS)识别未归类突变。
  • 另用Los Alamos HIV-1数据库的药物初治序列进行相同INT-WAS分析,以检验 identified 突变是否在DTG治疗病毒血症者中富集。

主要发现

  • 382条序列中104条(27.2%)显示至少 intermediate 水平DTG耐药。
  • 12个未归类为主要或辅助耐药突变的整合酶突变(S39R、L45I、I72L、L74I、V79I、I113V、S119R、K156N、I208M、T218M、A265V、R284G)与预测DTG耐药显著相关。
  • V79I的aOR为167.1(95% CrI 17.9–2947.6),I72L的aOR为65.6(95% CrI 6.6–1273.7)。
  • S39R、L45I、V79I、S119R和K156N与已建立的INSTI耐药通路相关。
  • I72L、L74I、V79I、K156N、I208M和R284G在DTG治疗病毒血症者序列中较药物初治序列过度代表。

临床怎么用

  • 对非洲非B亚型HIV-1感染者进行整合酶基因型耐药检测时,应关注V79I、I72L等未归类突变与DTG耐药的关联。
  • 解读DTG耐药时需注意当前耐药突变分类可能未涵盖所有相关突变,必要时结合治疗史和病毒学应答综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrase mutations associated with dolutegravir resistance have been well characterized, but based on limited data from non-B subtypes. OBJECTIVES: We aim to identify potential integrase mutations not currently classified as integrase strand transfer inhibitor (INSTI) resistance mutations (DRMs) in individuals with viremia on dolutegravir-based regimens. METHODS: We included integrase sequences from DTG RESIST study sites in African countries. These were interpreted using Stanford HIVdb v9.8. We used a viral genome-wide association study-like approach restricted to the integrase region (INT-WAS) to identify mutations not classified as major or accessory INSTI DRMs but occurring more frequently in sequences carrying major INSTI DRMs than in those without major INSTI DRMs. We performed the same INT-WAS analysis with drug-naïve sequences from the Los Alamos HIV-1 database to test whether these identified mutations were enriched among sequences from individuals with viraemia whilst receiving DTG-based treatment. RESULTS: Among 382 sequences, 104 (27.2%) showed at least intermediate dolutegravir resistance. Twelve integrase mutations not classified as major or accessory DRMs (S39R, L45I, I72L, L74I, V79I, I113V, S119R, K156N, I208M, T218M, A265V, and R284G) were significantly associated with predicted DTG resistance. Among them, V79I [adjusted odds ratio (aOR) 167.1, 95% credible interval (CrI) 17.9-2947.6] and I72L (aOR 65.6, 95% CrI 6.6-1273.7) were strongly associated. S39R, L45I, V79I, S119R, and K156N were linked to established INSTI resistance pathways, and I72L, L74I, V79I, K156N, I208M, and R284G were overrepresented in sequences from viraemic individuals on DTG-based treatment relative to drug-naïve sequences. CONCLUSIONS: We identified several amino acid substitutions outside the established DRMs that are strongly associated with predicted dolutegravir resistance. Dolutegravir resistance evolution is complex and likely involves mutations not currently classified as DRMs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Han N, Loosli T, Sauermann M, et al. Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study. J Antimicrob Chemother. 2026. PMID: 41873438. doi:10.1093/jac/dkag088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。